EDX Medical Group PLCAQUIS: EDX

EDX Medical Group: Appointment of CEO and board changes

· Issued by EDX Medical Group PLC via RNS

Summary by 6ix AI

EDX Medical Group plc, which develops and supplies digital diagnostic products and services for the early detection and treatment of major diseases, appointed Deputy Chairman Martin Walton as Chief Executive Officer with immediate effect, succeeding co-founder Dr Michael Hudson.

Key details

  • Dr Michael Hudson stepped down from the board with effect from close of business on November 16, 2026, and will continue to support the company as a consultant and as Director, International Strategy & Partnerships.
  • Professor Sir Christopher Evans, OBE, founder and Chief Scientific Officer of EDX Medical, has been appointed Deputy Chairman.
  • Martin Walton has more than 35 years' experience in finance and investment, latterly as vice chair, Europe and Asia Pacific, of a major Canadian bank, and has spent 15 years as an investor or officer in global life sciences companies, including Verona Pharma, Kymab, Arix Bioscience and Simbec-Orion.

6ix AI wrote this summary from the release below and checked it against the release.

EDX Medical Group PLC
17 November 2026

5e755ae6-7740-4e80-8ebc-c4ab684059c8.jpg

17 November 2026

EDX Medical Group plc · EDX

("EDX Medical" or the "Group" or "the Company”)

CEO APPOINTMENT & BOARD CHANGES

CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces the Company has appointed Martin Walton as Chief Executive Officer.

Martin Walton, currently Deputy Chairman of the Company, succeeds with immediate effect Dr Michael Hudson who as co-founder will continue to support the company as a consultant and Director, International Strategy & Partnerships, but has stepped down from the EDX Medical board with effect from close of business on 16 November 2026.

Professor Sir Christopher Evans, OBE, founder and Chief Scientific Officer of EDX Medical, has been appointed Deputy Chairman.

Martin Walton has more than 35 years' experience in finance and investment, latterly as vice chair, Europe and Asia Pacific, of a major Canadian bank. He has spent 15 years as an investor or officer in global life sciences companies, including Verona Pharma, Kymab, Arix Bioscience and Simbec-Orion. He has completed multiple corporate transactions creating value in private and publicly listed companies as well as building and overseeing commercial operations.

Dr Mike Owen, chairman of EDX Medical, commented: “EDX Medical is delighted to announce Martin’s appointment as CEO. This reflects the growth phase the Company has reached, and Martin’s extensive sector experience is a great asset as we drive forward our commercial operations.

“We are extremely grateful to Mike Hudson for his contribution as CEO from the earliest days of EDX Medical and look forward to him fulfilling an extremely important international and partnerships’ role.”

Professor Sir Christopher Evans, founder of EDX Medical, commented: "The board of EDX Medical has been strengthened significantly recently with the addition of three highly experienced independent non-executive directors and Martin’s financial and commercial experience made him an obvious choice to build on Mike Hudson’s success and lead the executive team as we continue to expand our commercial operations.”

ENDS

Contacts:

EDX Medical Group plc

Martin Walton, Chief Executive Officer

+44 (0) 7917531288

martin@edxmedical.com

Canaccord Genuity Limited (Nominated Adviser and Broker)

Stuart Andrews

+44 (0) 20 7523 8318

Media House International

Ramsay Smith

Gary McQueen

+44 (0)7788 414856

ramsay@mediahouse.co.uk

+ 44 (0)7834 694609

gary@mediahouse.co.uk

IFC Advisory (Investor Relations)

Graham Herring

Tim Metcalfe

+44 (0) 203 934 6630

About EDX Medical Group plc

EDX Medical Group plc is listed on the AIM market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

EDX Medical Group PLC on 6ix

Story so far

Earlier from EDX Medical

All EDX Medical news releases